Table 2: Summary of WHO Position Papers - Recommended Routine Immunizations for Children

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Age of 1st Dose</th>
<th>Doses in Primary Series</th>
<th>Interval Between Doses</th>
<th>Booster Dose</th>
<th>Considerations (see footnotes for details)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>1st to 2nd Doses</td>
<td>2nd to 3rd Doses</td>
<td>3rd to 4th Doses</td>
</tr>
<tr>
<td>BCG 1</td>
<td>As soon as possible after birth</td>
<td>1</td>
<td>4 weeks (min) with DTP1</td>
<td>4 weeks (min) with DTP2</td>
<td>4 weeks (min), with DTP3</td>
</tr>
<tr>
<td>Hepatitis B 2</td>
<td>Option 1 As soon as possible after birth (&lt;24h)</td>
<td>3</td>
<td>4 weeks (min) with DTP1</td>
<td>4 weeks (min) with DTP2</td>
<td>4 weeks (min), with DTP3</td>
</tr>
<tr>
<td></td>
<td>Option 2 As soon as possible after birth (&lt;24h)</td>
<td>4</td>
<td>4 weeks (min) with DTP1</td>
<td>4 weeks (min) with DTP2</td>
<td>4 weeks (min), with DTP3</td>
</tr>
<tr>
<td>Polio 3</td>
<td>OPV + IPV 6 weeks (see footnote for birth dose)</td>
<td>4</td>
<td>4 weeks (min) with DTP1</td>
<td>4 weeks (min) with DTP2</td>
<td>4 weeks (min), with DTP3</td>
</tr>
<tr>
<td></td>
<td>IPV / OPV Sequential 8 weeks (IPV 1st) 1-2 IPV 2 OPV 4-8 weeks</td>
<td>1</td>
<td>4-8 weeks</td>
<td>4-8 weeks</td>
<td>4-8 weeks</td>
</tr>
<tr>
<td></td>
<td>IPV 8 weeks</td>
<td>3</td>
<td>4-8 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polio 3</td>
<td>Option 1 6 weeks (min)</td>
<td>3</td>
<td>4 weeks (min) - 8 weeks</td>
<td>4 weeks (min) - 8 weeks</td>
<td>1-6 years of age (see footnote)</td>
</tr>
<tr>
<td></td>
<td>Option 2 59 weeks (max)</td>
<td>2-3</td>
<td>4 weeks (min) with DTP2</td>
<td>4 weeks (min) with DTP3</td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b 5</td>
<td>Option 1 6 weeks (min)</td>
<td>3</td>
<td>4 weeks (min) with DTP2</td>
<td>4 weeks (min) with DTP3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Option 2 59 weeks (max)</td>
<td>2-3</td>
<td>8 weeks (min) if only 2 doses</td>
<td>4 weeks (min) if 3 doses</td>
<td></td>
</tr>
<tr>
<td>Pneumococcal (Conjugate) 6</td>
<td>Option 1 6 weeks (min)</td>
<td>3</td>
<td>4 weeks (min)</td>
<td>4 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Option 2 6 weeks (min)</td>
<td>2</td>
<td>8 weeks (min)</td>
<td></td>
<td>9-15 months</td>
</tr>
<tr>
<td>Rotavirus 7</td>
<td>Rotarix 6 weeks (min) with DTP1</td>
<td>2</td>
<td>4 weeks (min) with DTP2</td>
<td></td>
<td>Vaccine options</td>
</tr>
<tr>
<td></td>
<td>Rota Teq 6 weeks (min) with DTP1</td>
<td>3</td>
<td>4 weeks (min) - 10 weeks with DTP2</td>
<td>4 weeks (min) with DTP3</td>
<td></td>
</tr>
<tr>
<td>Measles 8</td>
<td>9 or 12 months (6 months min, see footnote)</td>
<td>2</td>
<td>4 weeks (min) (see footnote)</td>
<td></td>
<td>Combination vaccine; HIV early vaccination; Pregnancy</td>
</tr>
<tr>
<td>Rubella 9</td>
<td>9 or 12 months with measles containing vaccine</td>
<td>1</td>
<td></td>
<td></td>
<td>Achieve and sustain 80% coverage Combination vaccine and Co-administration; Pregnancy</td>
</tr>
<tr>
<td>HPV 10</td>
<td>As soon as possible from 9 years of age</td>
<td>2</td>
<td>6 months (min)</td>
<td></td>
<td>Target 9-13 year old girls Pregnancy Older age groups ≥ 15 years HIV and immunocompromised</td>
</tr>
</tbody>
</table>

Refer to [http://www.who.int/immunization/documents/positionpapers/] for table & position paper updates.

This table summarizes the WHO vaccination recommendations for children. The ages/epochs cited are for the development of country-specific schedules and are not for health workers.

National schedules should be based on local epidemiologic, programmatic, resource & policy considerations. While vaccines are universally recommended, some children may have contraindications to particular vaccines.
Table 2: Summary of WHO Position Papers - Recommended Routine Immunizations for Children

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Age of 1st Dose</th>
<th>Doses in Primary Series</th>
<th>Interval Between Doses</th>
<th>Booster Dose</th>
<th>Considerations (see footnotes for details)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Japanese Encephalitis</strong>&lt;sup&gt;11&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse-brain derived Live attenuated</td>
<td>1 year</td>
<td>2</td>
<td>4 weeks (min)</td>
<td></td>
<td>After 1 year and every 3 years up to 10-15 years of age</td>
</tr>
<tr>
<td></td>
<td>9-12 months</td>
<td>1</td>
<td></td>
<td></td>
<td>Vaccine options</td>
</tr>
<tr>
<td><strong>Yellow Fever</strong>&lt;sup&gt;12&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9-12 months with measles containing vaccine</td>
<td>1</td>
<td></td>
<td></td>
<td>After 1 year</td>
</tr>
<tr>
<td><strong>Tick-Borne Encephalitis</strong>&lt;sup&gt;13&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 1 yr FSME-Immun and Encepur ≥ 3 yrs TBE_Moscow and EnceVir</td>
<td>3</td>
<td>1-3 months FSME-Immun and Encepur 1-7 months TBE-Moscow and EnceVir</td>
<td>5-12 months FSME-Immun and Encepur 12 months TBE-Moscow and EnceVir</td>
<td>At least 1 Every 3 years (see notes)</td>
<td>Definition of high-risk Vaccine options Timing of booster</td>
</tr>
</tbody>
</table>

**Recommendations for children residing in certain regions**

**Recommendations for children in some high-risk populations**

<table>
<thead>
<tr>
<th>Typhoid&lt;sup&gt;14&lt;/sup&gt;</th>
<th>Vi PS Capsules 5 years (min) (see footnote)</th>
<th>1</th>
<th>1 day</th>
<th>1 day</th>
<th>1 day</th>
<th>Every 3 years</th>
<th>Definition of high risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ty21a</td>
<td>2 years (min) 3 or 4 (see footnote)</td>
<td>3 (2-5 years) 2 (≥6 years) ≥ 7 days (min) &lt; 6 weeks (max)</td>
<td>≥ 7 days (min) &lt; 6 weeks (max)</td>
<td>Every 6 months Every 2 years</td>
<td>Minimum age Definition of high risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholera&lt;sup&gt;15&lt;/sup&gt;</td>
<td>Dukoral (WC-rBS) 1 year (min)</td>
<td>2</td>
<td>14 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shanchol and mORCVAX 1 year (min)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal&lt;sup&gt;16&lt;/sup&gt;</td>
<td>MenA conjugate 1-29 years</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2-11 months</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥12 months</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Quadrivalent conjugate 9-23 months ≥2 years</td>
<td>2</td>
<td>12 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥2 years</td>
<td>1</td>
<td></td>
<td></td>
<td>After 1 year</td>
<td>Definition of high risk; Vaccine options</td>
<td></td>
</tr>
<tr>
<td>Hepatitis A&lt;sup&gt;17&lt;/sup&gt;</td>
<td>1 year</td>
<td>At least 1</td>
<td></td>
<td></td>
<td></td>
<td>Level of endemicity; Vaccine options; Definition of high risk groups</td>
<td></td>
</tr>
<tr>
<td>Rabies&lt;sup&gt;18&lt;/sup&gt;</td>
<td>As required</td>
<td>3</td>
<td>7 days</td>
<td>14-21 days</td>
<td></td>
<td></td>
<td>Definition of high risk, booster</td>
</tr>
</tbody>
</table>

**Recommendations for children receiving vaccinations from immunization programmes with certain characteristics**

| Mumps<sup>19</sup> | 12-18 months with measles containing vaccine | 2 | 1 month (min) to school entry | | Coverage criteria > 80%; Combo vaccine |
|---------------------|---------------------------------------------|---|-----------------------------| | |
| Influenza (Inactivated)<sup>20</sup> | 6 months (min) | 2 (<9 years) 1 (>9 years) | | Coverage criteria > 80%; Combo vaccine |

(Updated 30 May 2014)
3 Polio


**OPV plus IPV**

- WHO no longer recommends an OPV-only vaccination schedule. For all countries currently using OPV only, at least 1 dose of IPV should be added to the schedule.
- In polio-endemic countries and in countries at high risk for importation and subsequent spread, WHO recommends an OPV birth dose (a zero dose) followed by a primary series of 3 OPV and at least 1 IPV doses.
- The birth dose of OPV should be administered at birth, or as soon as possible after birth, to maximize the seroconversion rates with subsequent doses and to induce mucosal protection.
- The primary series consisting of 3 OPV doses plus 1 IPV dose can be initiated from the age of 6 weeks with a minimum interval of 4 weeks between the OPV doses. If 1 dose of IPV is used, it should be given from 14 weeks of age (when maternal antibodies have diminished and immunogenicity is significantly higher) and can be co-administered with an OPV dose.
- The primary series can administered according to the regular schedules of national immunization programmes, for example at 6, 10, and 14 weeks (OPV1, OPV2, OPV3+IPV), or at 2, 4, and 6 months (OPV1, OPV2+IPV, OPV3 or OPV1, OPV2, OPV3+IPV). Both OPV and IPV may be co-administered with other infant vaccines.
- For infants starting the routine immunization schedule late (age > 3 months) the IPV dose should be administered at the first immunization contact.
- As an alternative to the intramuscular injection of a full IPV dose, countries can consider using a 1/5 fractional doses via the intradermal route, but the programmatic cost and logistical implications of this option should be considered.
- There is no demonstrated benefit from booster doses of OPV after completion of the recommended primary series of 3 OPV doses and at least 1 IPV dose.
- The implementation of the new schedule (3 OPV doses + 1 IPV dose) does not replace the need for supplemental immunization activities (SIAs). Those countries with insufficient routine immunization coverage that rely on SIAs to increase population immunity should continue to do so until routine immunization improves.

### Sequential IPV–OPV schedule

- In countries with high immunization coverage (e.g. 90%–95%) and low importation risk (neighbouring countries and connections with similarly high immunization coverage) an IPV–OPV sequential schedule can be used when VAPP is a significant concern.
- The initial administration of 1 or 2 doses of IPV should be followed by ≥2 doses of OPV to ensure both sufficient levels of protection in the intestinal mucosa and a decrease in the burden of VAPP.
- For sequential IPV–OPV schedules, WHO recommends that IPV be given at 2 months of age (e.g. a 3-dose IPV-OPV-OPV schedule) or at 2 months and 3–4 months of age (e.g. a 4-dose IPV-OPV-OPV schedule) followed by at least 2 doses of OPV. Each of the doses in the primary series should be separated by 4–8 weeks depending on the risk of exposure to poliovirus in early childhood.
IPV-only schedule

- An IPV-only schedule may be considered in countries with both sustained high immunization coverage and the lowest risk of both WPV importation and transmission.
- A primary series of 3 doses of IPV should be administered beginning at 2 months of age.
- If the primary series begins earlier (e.g. with a 6, 10 and 14-week schedule) then a booster dose should be given after an interval of ≥6 months (for a 4-dose schedule).

4 DTP (Diphtheria, Tetanus and Pertussis)

- Recommended for three doses during the first year of life. In areas where pertussis is of particular risk to young infants, DTP should be started at 6 weeks with 2 subsequent doses at intervals of 4-8 weeks each. The last dose of the primary series should be completed by the age of 6 months.
- The duration of immunological protection will be extended in many instances if an additional booster is given later.
- Diphtheria booster - to compensate for the loss of natural diphtheria boosting in some areas, childhood boosters should be given. The optimal timing of and number of diphtheria-containing booster doses should be based on epidemiological surveillance as well as on immunological and programmatic considerations.
- Tetanus toxoid containing booster - A childhood tetanus immunization schedule of 5 doses is recommended. Boosters are ideally administered in early childhood and during adolescence e.g. 12-15 years. Tetanus booster doses may use either DTP or Td vaccines depending on the child’s age. Td should be used for tetanus and diphtheria booster doses after the age of 7 years.
- Pertussis vaccine: Neo-natal immunization, and vaccination of pregnant women and household contacts (“cocooning”) against pertussis is not recommended by WHO.
- Both acellular (aP) and whole cell pertussis (wP) containing vaccines have excellent safety records, and protection against severe pertussis in infancy and early childhood can be obtained with wP or aP vaccine. Changing among or within the wP and aP vaccine groups is unlikely to interfere with the safety or immunogenicity of these vaccines.
- Only aP-containing vaccines should be used for vaccination of those >6 years.
- Pertussis containing booster - A booster dose is recommended for children age 1-6 years, preferably during the second year of life. The booster should be given > 6 months after the last primary dose. Completion of this schedule (primary series plus booster) is expected to ensure protection against pertussis for > 6 years.
- Delayed or interrupted DTP series - Children 1-7 years or older who have not previously been immunized should receive three doses of wP or aP vaccine, with an interval of 2 months between the first and second dose and an interval of 6-12 months between the second and third. Children whose vaccination series has been interrupted should have their series resumed, without repeating previous doses. For unvaccinated individuals 7 years of age and older, Td combination vaccine can be administered, 2 doses 1-2 months apart and a third dose after 6-12 months can be used with subsequent boosters at least 1 year apart for a total of 5 appropriately spaced doses to obtain same long term protection. See position paper for details of interrupted immunization schedules.

5 Haemophilus influenzae type b (Hib)

- The use of Hib vaccines should be part of a comprehensive strategy to control pneumonia including exclusive breastfeeding for six months, hand washing with soap, improved water supply and sanitation, reduction of household air pollution, and improved case management at community and health facility levels.
- WHO recommends that any one of the following Hib immunization schedules may be followed: 3 primary doses without a booster (3p); 2 primary doses plus a booster (2p+1); and 3 primary doses with a booster (3p+1).
- Because serious Hib disease occurs most commonly in children aged between 4 months and 18 months, immunization should start from 6 weeks of age, or as early as possible thereafter.
- The number of primary doses should be set after consideration of the local epidemiology, vaccine presentation (Hib conjugate monovalent vaccine versus Hib conjugate vaccine in combination with other antigens) and how this fits into the overall routine immunization schedule.
- In countries where the peak burden of severe Hib disease occurs in young infants, providing 3 doses of vaccine early in life may confer a greater benefit.
- In some settings (e.g. where the greatest disease morbidity and mortality occur later, or where rate reductions of disease are not fully sustained after the routine use of Hib vaccine), it might be advantageous to give a booster dose by following either a 2p+1 or 3p+1 schedule.
- The interval between doses should be at least 4 weeks if 3 primary doses are given, and at least 8 weeks if 2 primary doses are given. Booster doses should be administered at least six months after completion of the primary series.
- If the vaccination course has been interrupted, the schedule should be resumed without repeating the previous dose. Children who start vaccination late, but are aged under 12 months, should complete the vaccination schedule (e.g. have 3 primary doses or 2 primary doses plus a booster).
- When a first dose is given to a child older than 12 months of age, only one dose is recommended.
- Hib vaccine is not required for healthy children after 5 years of age.
- The Hib conjugate vaccine is contraindicated in people with known allergies to any component of the vaccine. There are no other known contraindications or precautions.

6 Pneumococcal (Conjugate)

- Pneumococcal conjugate vaccines (PCVs) are considered safe in all target groups for vaccination, also in immunocompromise individuals. The vaccines are not currently licensed for use in age groups that include women of childbearing age. Although theoretically highly unlikely to be harmful, there is no information on the safety of PCV10 and PCV13 during pregnancy.
- Except for very rare anaphylactic reactions that may follow the administration of any medicine, there are no contraindications to the use of these vaccines. However, it is advisable to defer vaccination until after an acute infection with temperature >39 °C.
- When injected at different sites, PCVs can be administered concurrently with any other vaccines in infant immunization programmes.
- When primary immunization is initiated with one of these vaccines, it is recommended that remaining doses are administered with the same product. Interchangeability between PCV10 and PCV13 has not yet been documented. However, if it is not possible to complete the series with the same type of vaccine, the other PCV product should be used.
- For infants, 3 primary doses (the 3p+0 schedule) or, as an alternative, 2 primary doses plus a booster (the 2p+1 schedule).
- In choosing between the 3p+0 and 2p+1 schedules, countries should consider locally relevant factors including the epidemiology of pneumococcal disease, the likely coverage, and the
timeliness of the vaccine doses.

- If disease incidence peaks in young infants (<32 weeks of age), a 2p+1 schedule might not offer optimal individual protection for certain serotypes (e.g. 6B, 23F) compared to a 3p+0 schedule, particularly in the absence of herd protection.

- In contrast, higher antibody levels are induced by the third (booster) dose in a 2p+1 schedule compared to the third dose in a 3p+0 schedule. This may be important for duration of protection or effectiveness against some serotypes.

- If the 3p+0 schedule is used, vaccination can be initiated as early as 6 weeks of age with an interval between doses of 4–8 weeks, depending on programmatic convenience.

- If the 2p+1 schedule is selected, the 2 primary doses should ideally be completed by six months of age, starting as early as 6 weeks of age with a minimum interval of 8 weeks or more between the two doses (for infants aged ≥7 months a minimum interval of 4 weeks between doses is possible). One booster dose should be given between 9–15 months of age.

- Previously unvaccinated or incompletely vaccinated children (including those who had laboratory confirmed invasive pneumococcal disease) should be vaccinated using the recommended age-appropriate regimens. Interrupted schedules should be resumed without repeating the previous dose.

- HIV-positive infants and pre-term neonates who have received their 3 primary vaccine doses before reaching 12 months of age may benefit from a booster dose in the second year of life.

- Catch-up vaccination as part of introduction will accelerate herd protection and therefore the PCV impact on disease and carriage. Maximized protection at the time of introduction of PCV10 or PCV13 can be achieved by providing 2 catch-up dose(s) at an interval of at least 8 weeks to unvaccinated children aged 12–24 months and to children aged 2–5 years who are at high risk of pneumococcal infection.

- Further data are needed from different epidemiological settings on the impact of large-scale PCV vaccination of individuals >50 years of age in order to establish the relative priority of immunisation programmes in that age group. However, given the documented effects of herd protection in adult age groups following routine infant immunization with PCV7, higher priority should normally be given to introducing and maintaining high coverage of infants with PCVs.

- The use of pneumococcal vaccine should be seen as complementary to the use of other pneumococcal vaccines or PCV13 can be achieved by providing 2 catch-up dose(s) at an interval of at least 8 weeks to unvaccinated children aged 12–24 months and to children aged 2–5 years who are at high risk of pneumococcal infection.

- Apart from a low risk of intussusception (about 1-2 per 100 000 infants vaccinated) the current rotavirus vaccines are considered safe and well tolerated.

- Severe allergic reaction (e.g. anaphylaxis) after a previous dose, and severe immunodeficiency including severe combined immunodeficiency, are contraindications for rotavirus vaccination.

- The use of rotavirus vaccines should be part of a comprehensive strategy to control diarrhoeal diseases with the scaling up of both intervention (exclusive breastfeeding for 6 months, vitamin A supplementation, safe drinking water, hygiene/handwashing with soap, and sanitation) and treatment (low-osmolarity ORS, zinc and continued feeding).

### 6 Measles


- Reaching all children with two doses of measles containing vaccine (MCV) should be the standard for all national immunization programmes.

- Delivery of the second dose (MCV2) may occur either at a scheduled age through routine services or periodically through mass campaigns, depending on which strategy achieves the higher coverage. The routine MCV2 dose is generally added to the routine immunization schedule in countries that have achieved >80% coverage of measles first dose (MCV1) at the national level for 3 consecutive years as determined by the most accurate means available (e.g. survey or WHO/UNICEF estimates). In general, countries that do not meet this criterion should prioritize improving MCV1 coverage and conducting high-quality follow-up SIAs, rather than adding MCV2 to their routine schedule.

- In countries with ongoing transmission in which the risk of measles mortality remains high, MCV1 should be given at age 9 months. MCV2 should be given between 15-18 months, as providing MCV2 in the 2nd year of life reduces the rate of accumulation of susceptible children and the risk of an outbreak.

- In countries with low rates of measles transmission (that is, those that are near elimination) and where there is a low risk of measles infection among infants, the first dose may be administered at age 12 months to take advantage of the higher seroconversion rates achieved at this age (>90% seroconversion). In these countries the optimal age for delivering a routine 2nd dose of measles is based on programmatic considerations that achieve the highest coverage and hence the highest population immunity. Administration of the second dose at age 15-18 months ensures early protection of the individual, slows accumulation of susceptible young children and may correspond with other routine immunizations (for example, DTP booster). If first dose coverage is high (>90%) and school enrolment is high (>95%), giving the second dose at school entry may be an effective strategy for achieving high coverage and preventing outbreaks in schools.

- Combined vaccines (Measles and Rubella or Measles, Mumps and Rubella) may not be optimal for use in countries where vaccine coverage for measles vaccine of at least 80% cannot be achieved or maintained.

- Measles vaccination should be routinely administered to potentially susceptible, asymptomatic HIV-positive children and adults. In areas where there is a high incidence of both HIV infection and measles, a single dose of measles vaccine is recommended.

### 7 Rotavirus


- Recommended to be included in all national immunization programmes.

- Early immunization is favoured with the first dose of rotavirus vaccine to be administered from 6 weeks of age, however, in order to benefit those who may come late infants can receive doses without age restriction. Because of the typical age distribution of rotavirus gastroenteritis (RVGE), rotavirus vaccination of children >24 months of age is not recommended.

- Rotarix is administered orally in a 2-dose schedule at the time of DTP1/penta and DTP2/penta with an interval of at least 4 weeks between doses.

- RotaTeq vaccine is administered orally in a 3-dose schedule at the time of DTP1/penta, DTP2, and DTP3 contacts, with an interval of at least 4 weeks between doses.

- Rotavirus vaccinations can be administered simultaneously with other vaccines in the infant immunization programme.

- Apart from a low risk of intussusception (about 1-2 per 100 000 infants vaccinated) the current rotavirus vaccines are considered safe and well tolerated.

- Severe allergic reaction (e.g. anaphylaxis) after a previous dose, and severe immunodeficiency including severe combined immunodeficiency, are contraindications for rotavirus vaccination.

- Precautions are necessary if there is a history of intussusception or intestinal malformations, chronic gastrointestinal disease, and severe acute illness. Vaccination should be postponed in case of ongoing acute gastrointestinal or fever with moderate to severe illness.

- The use of rotavirus vaccines should be part of a comprehensive strategy to control diarrhoeal diseases with the scaling up of both intervention (exclusive breastfeeding for 6 months, vitamin A supplementation, safe drinking water, hygiene/handwashing with soap, and sanitation) and treatment (low-osmolarity ORS, zinc and continued feeding).
Rubella

- All countries that have not yet introduced rubella vaccine, and are providing 2 doses of measles vaccine using routine immunization, or SIAs, or both, should consider including rubella containing vaccines (RCVs) in their immunization programme. Countries planning to introduce RCVs should review the epidemiology of rubella, including the susceptibility profile of the population; assess the burden of CRS; and establish rubella and CRS prevention as a public health priority.
- Because rubella is not as highly infectious as measles and because the effectiveness of 1 dose of an RCV is > 95% even at 9 months of age, only 1 dose of rubella vaccine is required to achieve rubella elimination if high coverage is achieved. However, when combined with measles vaccination, it may be easier to implement a second dose of RCV’s using the same combined MR vaccine or MMR vaccine for both doses.
- There are two general approaches to the use of rubella vaccine: (i) exclusive focus on reducing CRS by immunizing adolescent girls or women of childbearing age, or both groups, to provide individual protection; (ii) focus on interrupting transmission of rubella virus and eliminating rubella and CRS, by introducing rubella vaccination into the routine childhood immunization schedule combined with the vaccination of older age groups who are susceptible to rubella.
- To avoid the potential of an increased risk of CRS, countries should achieve and maintain immunization coverage of 80% or greater with at least 1 dose of an RCV delivered through routine services or regular campaigns, or both.
- The first dose of RCV can be delivered at 9 or 12 months depending on the measles vaccination schedule.
- RCV’s can be administered concurrently with inactivated vaccines. As a general rule, live vaccines should be given either simultaneously with RCV’s, or at least 4 weeks apart. An exception to this is oral polio vaccine, which can be given at any time before or after RCV’s without interfering in the response to either vaccine. Interference may occur between MMR and yellow fever vaccines if they are simultaneously administered to children < 2 years of age.
- Because of a theoretical, but never demonstrated, teratogenic risk rubella vaccination in pregnant women should be avoided in principle, and those planning a pregnancy are advised to avoid pregnancy for 1 month following vaccination.
- Administration of blood or blood products before or shortly after vaccination may interfere with vaccine efficacy. If using only rubella vaccines persons who received blood products should wait at least 3 months before vaccination and, if possible, blood products should be avoided for up to 2 weeks postvaccination. Vaccinated persons are not eligible to donate blood for 1 month after vaccination.

Human Papillomavirus (HPV)


- Recommended target population: girls aged 9–13 years, prior to initiation of sexual activity.
- A 2-dose schedule with an interval of at least 6 months between doses is recommended for girls aged <15 years (even for the girls aged ≥15 years at the time of the second dose).
- If for any reason interval between the first and second doses is shorter than 6 months, then a 3rd dose should be given at least 6 months after the first dose.
- The 3-dose schedule (0, 1–2, 6 months) remains recommended for girls ≥ 15 years of age and for immunocompromised individuals, including those known to be HIV-infected.
- These schedule recommendations apply to both the bivalent and quadrivalent vaccines.
- Both HPV vaccines are non-live and non-infectious and can be co-administered with other live and non-live vaccines using separate syringes and different injection sites.
- Data on the safety of HPV vaccination in pregnancy are limited, and HPV vaccination of pregnant women should be avoided.
- HPV vaccines should be introduced as part of a coordinated strategy to prevent cervical cancer.
- HPV vaccination of males for prevention of cervical cancer is not recommended at this time as the measles vaccine.
- Vaccine options - Three types of vaccines are available: (1) a cell culture-based live attenuated, (2) a cell culture-based inactivated and (3) an inactivated mouse brain-derived. The WHO position paper provides recommendations for the mouse brain-derived and live attenuated vaccines.
- Booster - If administering cell culture-based live-attenuated vaccine, a booster dose is currently recommended after an interval of one year, even though observational studies suggest longer-term protection after a single dose. If using mouse brain-derived vaccine, a booster dose should be administered after an interval of one year then every 3 years until 10-15 years of age.

Japanese Encephalitis (JE)

- JE vaccine should be given in all areas where JE constitutes a public health problem.
- Vaccine options - Three types of vaccines are available: (1) a cell culture-based live attenuated, (2) a cell culture-based inactivated and (3) an inactivated mouse brain-derived. The WHO position paper provides recommendations for the mouse brain-derived and live attenuated vaccines.
- Booster - If administering cell culture-based live-attenuated vaccine, a booster dose is currently recommended after an interval of one year, even though observational studies suggest longer-term protection after a single dose. If using mouse brain-derived vaccine, a booster dose should be administered after an interval of one year then every 3 years until 10-15 years of age.

Yellow Fever

- WHO recommends that all endemic countries should introduce YF vaccine into their routine immunization programmes.
- A single dose of YF vaccine is sufficient to confer sustained life-long protective immunity against YF disease; a booster dose is not necessary.
- It is recommended that YF vaccine be given to children at age 9-12 months at the same time as the measles vaccine.
- The vaccine is contraindicated in children aged <6 months and is not recommended for those aged 6–8 months during epidemics when the risk of infection with the YF virus is very high. Other contraindications for YF vaccination are severe hyper-sensitivity to egg antigens and severe immunodeficiency.
- Preventive mass vaccination campaigns are recommended for inhabitants of areas at risk of YF where there is low vaccination coverage. Vaccination should be provided to everyone aged ≥ 9 months, in any area with reported cases. Noting that YF is a live vaccine, a risk-benefit assessment should be undertaken for all pregnant and lactating women.
• Vaccine should be offered to all unvaccinated travelers aged ≥ 9 months, travelling to and from at-risk areas, unless they belong to the group of individuals for whom YF vaccination is contraindicated.

• YF vaccine may be administered simultaneously with other vaccines.

13 Tick-Borne Encephalitis (TBE)


• Since the incidence of tick-borne encephalitis may vary considerably between and even within geographical regions, public immunization strategies should be based on risk assessments conducted at country, regional or district level, and they should be appropriate to the local endemic situation. Therefore, establishing case reporting of the disease is essential before deciding on the most appropriate preventive measures to be taken.

• In areas where the disease is highly endemic (that is, where the average prevaccination incidence of clinical disease is ≥5 cases/100 000 population per year), implying that there is a high individual risk of infection, WHO recommends that vaccination be offered to all age groups, including children.

• Because the disease tends to be more serious in individuals aged >50-60 years this age group constitutes an important target for immunization.

• Where the prevaccination incidence of the disease is moderate or low (that is, the annual average during a 5-year period is <5/100 000) or is limited to particular geographical locations or certain outdoor activities, vaccination should target individuals in the most severely affected cohorts.

• People travelling from non-endemic areas to endemic areas should be offered vaccination if their visits will include extensive outdoor activities.

• Vaccination against the disease requires a primary series of 3 doses; those who will continue to be at risk should probably have ≥1 booster doses.

• Within the considerable range of acceptable dose intervals, the relevant national authorities should select the most rational primary schedule for their national, regional or district immunization programmes.

• Although there is a strong indication that the spacing of boosters could be expanded considerably from the intervals currently recommended by the manufacturers (every 3-5 years), the evidence is still insufficient for a definitive recommendation on the optimal frequency and number of booster doses. Countries should therefore continue to recommend the use of vaccines in accordance with local disease epidemiology and current schedules until more definitive information becomes available.

• For the vaccines manufactured in Austria and Germany (FSME-Immun and Encepur;1) that can be given starting from > 1 year of age an interval of 1–3 months is recommended between the first 2 doses, and 5–12 months between the second and third doses. When rapid protection is required, for example for people who will be travelling to endemic areas, the interval between the first 2 doses may be reduced to 1–2 weeks.

• With the vaccines manufactured in the Russian Federation (TBE-Moscow and EnceVir) the recommended intervals are 1–7 months between the first 2 doses, and 12 months between the second and third doses. Booster doses are recommended every 3 years for those at continued risk of exposure.

• The currently recommended booster interval should be maintained until more data have been obtained on the duration of protection induced by the Russian vaccines.

• Regardless of the duration of the delay, interrupted schedules should be resumed without repeating previous doses.

14 Typhoid


• Recommended for school-age and/or preschool-age children in areas where typhoid fever in these age groups is shown to be a significant public health problem, particularly where antibiotic-resistant S. Typhi is prevalent.

• Vaccine options - Vi polysaccharide typhoid vaccine requires one parenterally administered dose which may be given after the age of 2 years; the liquid form of Ty21a live oral vaccine (for use in individuals from the age of 2 years) is no longer available; the capsule form of Ty21a (for use in individuals from the age of 5 years) requires 3 or 4 orally administered doses. See position paper for further details.

• Booster - In most endemic settings, a booster dose of the concerned vaccine 3 to 7 years after the primary immunization seems appropriate.

15 Cholera


• In cholera-endemic countries, vaccinating the entire population is not warranted. Rather, vaccination should be targeted at high-risk areas and population groups. The primary targets for cholera vaccination in many endemic areas are preschool-aged and school aged children. Other groups that are especially vulnerable to severe disease and for which the vaccines are not contraindicated may also be targeted, such as pregnant women and HIV-infected individuals. Consider vaccinating older age groups if funding is available.

• Two types of oral cholera vaccines are available: (i) Dukoral (WC-rBS) and (ii) Sanchol and mORCVAX. The live attenuated single-dose vaccine (CVD 103-HgR) is no longer produced. The injectable vaccine is still manufactured in a few countries but its use is not recommended mainly because of its limited efficacy and short duration of protection.

• Dukoral is not licensed for children < 2 years. Children aged 2-5 years should receive 3 doses ≥7 days apart (but not more than 6 weeks). Intake of food and drink should be avoided for 1 hour before and after vaccination. If the interval between doses is delayed > 6 weeks, primary vaccination should be restarted. One booster dose is recommended every 6 months, and if the interval between primary immunization, and the booster is >6 months, primary immunization must be restarted.

• Adults and children ≥6 years should receive 2 doses of Dukoral ≥7 days apart (but not more than 6 weeks). Intake of food and drink should be avoided for 1 hour before and after vaccination. If the interval between doses is delayed > 6 weeks, primary vaccination should be restarted. A booster dose every 2 years is recommended. If the interval between the primary series and booster immunization is > 2 years, primary immunization must be repeated.

• Shanchol and mORCVAX: two liquid doses orally 14 days apart for individuals ≥1 year. A booster dose is recommended after 2 years.

16 Meningococcal


• Conjugate vaccines are preferred over polysaccharide vaccines due to their potential for herd protection and their increased immunogenicity, particularly in children <2 years of age.

• Both conjugate and polysaccharide vaccines are efficacious and safe when used in pregnant women.

• Monovalent MenA conjugate vaccine should be given as one single intramuscular dose to individuals 1-29 years of age. The possible need for a booster is not yet established.
**For monovalent MenC conjugate vaccine one single intramuscular dose is recommended for children aged >12 months, teenagers and adults. Children 2-11 months require 2 doses administered at an interval of at least 2 months and a booster about 1 year after. If the primary series is interrupted, vaccination should be resumed without repeating the previous dose.**

**Quadrivalent conjugate vaccines (A,C,W135,Y-D and A,C,W135,Y-CRM) should be administered as one single intramuscular dose to individuals > 2 years. A,C,W135,Y-D is also licensed for children 9-23 months of age, and given as a 2-dose series, 3 months apart beginning at age 9 months. If the primary series is interrupted, vaccination should be resumed without repeating the previous dose.**

**Meningococcal polysaccharide vaccines are less, or not, immunogenic in children under 2 years of age.**

**Meningococcal polysaccharide vaccines can be used for those > 2 years of age to control outbreaks in countries where limited economic resources or insufficient supply restrict the use of meningococcal conjugate vaccines. Polysaccharide vaccines should be administered to individuals > 2 years old as one single dose. One booster 3-5 years after the primary dose may be given to persons considered to be a continued high risk of exposure, including some health workers. See position paper for details.**

---

### Hepatitis A


**Hepatitis A vaccination is recommended for inclusion in the national immunization schedule for children ≥ 1 year if indicated on the basis of incidence of acute hepatitis A, change in the endemicity from high to intermediate, and consideration of cost-effectiveness.**

**In highly endemic countries almost all persons are asymptotically infected with HAV in childhood, which effectively prevents clinical hepatitis A in adolescents and adults. In these countries, large-scale vaccination programmes are not recommended.**

**Countries with improving socioeconomic status may rapidly move from high to intermediate endemicity. In these countries, a relatively large proportion of the adult population is susceptible to HAV and large-scale hepatitis A vaccination is likely to be cost-effective and therefore is encouraged.**

**For individual health benefit targeted vaccination of high-risk groups should be considered in low and very low endemicity settings. Those at increased risk of hepatitis A include travelers to areas of intermediate or high endemicity, those requiring life-long treatment with blood products, men who have sex with men, workers in contact with non-human primates, and injection drug users. In addition, patients with chronic liver disease are at increased risk for fulminant hepatitis A and should be vaccinated.**

**Inactivated HAV vaccine is licensed for intramuscular administration in a 2-dose schedule with the first dose given at the age of 3 years or older. The interval between the first and second dose is flexible (from 6 months up to 4-5 years) but is usually 6-18 months. Countries may consider a 1-dose schedule as this option seems comparable in terms of effectiveness, and is less expensive and easier to implement. However, in individuals at substantial risk of contracting hepatitis A and in immunocompromised individuals, a 2-dose schedule is preferred. Inactivated HAV vaccines produced by different manufacturers, including combined hepatitis A vaccines, are interchangeable. Apart from severe allergic reaction to the previous dose, there is no contraindication to their use. These vaccines can be co-administered simultaneously with other routine childhood vaccines, and should be considered for use in pregnant women at definite risk of HAV infection.**

**Live attenuated HAV vaccine is administered as a single subcutaneous dose to those ≥ 1 year of age. Severe allergy to components included in the live attenuated hepatitis A vaccine is a contraindication to their use. As a rule, live vaccines should not be used in pregnancy or in severely immunocompromised patients. There is no information available on co-administration of live attenuated hepatitis A vaccines with other routinely used vaccines.**

**Vaccination against hepatitis A should be part of a comprehensive plan for the prevention and control of viral hepatitis, including measures to improve hygiene and sanitation and measures for outbreak control.**

---

### Rabies


**Production and use of nerve-tissue rabies vaccines should be discontinued and replaced with cell-culture-based vaccines (CCVs).**

**Recommended for anyone who will be at continual, frequent or increased risk of exposure to the rabies virus, either as a result of their residence or occupation. Travellers with extensive outdoor exposure in rural high-risk areas where immediate access to appropriate medical care may be limited should also be vaccinated regardless of the duration of stay. Where canine rabies is a public health problem, WHO encourages studies on the feasibility, cost-effectiveness, and long-term impact of incorporating rabies vaccination into the immunization programme for infants and children.**

**The series is given by intramuscular or intradermal injection at 0, 7 and 21 or 28 days.**

**Intramuscular administration: For adults and children aged ≥2 years, the vaccine should always be administered in the deltoid area of the arm; for children aged < 2 years, the anterolateral area of the thigh is recommended. Rabies vaccine should not be administered in the gluteal area, as the induction of an adequate immune response may be less reliable.**

** Booster doses of rabies vaccines are not required for individuals living in or travelling to high-risk areas who have received a complete primary series of pre-exposure or post-exposure prophylaxis with a cell-culture-based rabies vaccine (CCV).**

**Periodic booster injections are recommended only for people whose occupation puts them at continual or frequent risk of exposure. If available, antibody monitoring is prefered to the administration of routine boosters.**

**Because vaccine-induced immunity persists in most cases for years, a booster is recommended only if rabies-virus neutralizing antibody titres fall to <0.5 IU/mL.**

**Antibody testing should be done every 6 months for people at risk of laboratory exposure to high concentrations of live rabies virus, and every 2 years for professionals who are not at continual risk of exposure through their activities, such as certain categories of veterinarians and animal health officers.**

---

### Mumps


**Recommended for use in high performing immunization programs with the capacity to maintain coverage over 80% and where mumps reduction is a public health priority.**

**If implemented, a combination vaccine of measles, mumps and rubella is recommended.**

---

### Seasonal Influenza (Inactivated Vaccine)


**The World Health Assembly recommended increased immunization coverage of high-risk groups including the elderly, in those countries where influenza vaccination policies exist (Reference: WHA56.19, 2003). See position paper for detailed description of high-risk groups.**

**Dose - If a child under 9 years of age requires vaccination and has not previously received influenza vaccine, a two-dose series with doses one month apart should be administered. Annual re-vaccination in all individuals and initial vaccination in individuals 9 years of age or older require only a single dose. Children aged 6-36 months should receive half the adult dose.**

---

**Table 2: Recommended Routine Immunization for Children (updated 30 May 2014)**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Age</th>
<th>Dose</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inactivated HAV vaccine</td>
<td>≥1 year</td>
<td>1 dose</td>
<td>0, 7, 21 or 28 days</td>
</tr>
<tr>
<td>Live attenuated HAV vaccine</td>
<td>≥1 year</td>
<td>1 dose</td>
<td>0, 7, 21 or 28 days</td>
</tr>
<tr>
<td>Inactivated influenza vaccine</td>
<td>&gt;6 months</td>
<td>1 dose</td>
<td>0, 7, 21 or 28 days</td>
</tr>
</tbody>
</table>

---

**For monovalent MenC conjugate vaccine one single intramuscular dose is recommended for children aged >12 months, teenagers and adults. Children 2-11 months require 2 doses administered at an interval of at least 2 months and a booster about 1 year after. If the primary series is interrupted, vaccination should be resumed without repeating the previous dose.**

---

**Quadrivalent conjugate vaccines (A,C,W135,Y-D and A,C,W135,Y-CRM) should be administered as one single intramuscular dose to individuals > 2 years. A,C,W135,Y-D is also licensed for children 9-23 months of age, and given as a 2-dose series, 3 months apart beginning at age 9 months. If the primary series is interrupted, vaccination should be resumed without repeating the previous dose.**

---

**Meningococcal polysaccharide vaccines are less, or not, immunogenic in children under 2 years of age.**

---

**Meningococcal polysaccharide vaccines can be used for those > 2 years of age to control outbreaks in countries where limited economic resources or insufficient supply restrict the use of meningococcal conjugate vaccines. Polysaccharide vaccines should be administered to individuals > 2 years old as one single dose. One booster 3-5 years after the primary dose may be given to persons considered to be a continued high risk of exposure, including some health workers. See position paper for details.**